Hamlet Pharma and SelectImmune Pharma merge to create an innovative pharmaceutical company with a broad and strong portfolio of projects for the...
This press release or the merger does not constitute an offer, either directly or indirectly in Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa or the United States, or in any other jurisdiction where such offer under the laws and regulations of such relevant jurisdiction would be prohibited by applicable law. Shareholders who are not resident in Sweden...
Taggar: hamlet, pharma, selectimmune
Läs hela artikeln på Dagens industriRelaterade nyheter
- Hamlet Pharma’s achievements regarded as ‘‘exceptional’’ by the European Commission after final review of the Horizon 2020 project
- Hamlet Pharma AB: Hamlet Pharma Q2 Interim Report October 2022 – December 2022
- Hamlet Pharma advertises in major health supplement - published in one of the world's leading international newspapers, The Guardian